Remission Evaluation of Metabolic Interventions in Type 2 Diabetes (REMIT Pilot Trial)

Phase 4 Completed 83 enrolled Population Health Research Institute Hamilton Health Sciences Corporation · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this pilot trial is to determine whether an intensive treatment with insulin glargine, metformin, acarbose and lifestyle can normalize blood glucose levels in patients with recently diagnosed type 2 diabetes mellitus when compared to standard diabetes care.

Timeline

Start: 2011-01
Primary completion: 2015-02
Completion: 2015-09

Outcome

Met primary endpoint

paper At 8 weeks, 50.0% of the 8-week intervention group vs 3.6% of controls achieved normoglycemia on therapy PMID 28324049 ↗

paper [relative risk (RR), 14.0; 95% confidence interval (CI), 1.97 to 99.38) PMID 28324049 ↗

paper at 16 weeks, these percentages were 70.4% in the 16-week group and 3.6% in controls (RR, 19.7; 95% CI, 2.83 to 137.13) PMID 28324049 ↗

Publications

Results McInnes N, Smith A, Otto R, Vandermey J, Punthakee Z, Sherifali D, Balasubramanian K, Hall S, Gerstein HC. Piloting a Remission Strategy in Type 2 Diabetes: Results of a Randomized Controlled Trial. J Clin Endocrinol Metab. 2017 May 1;102(5):1596-1605. doi: 10.1210/jc.2016-3373.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Acarbose	Unknown	—	Oral
Subject	Metformin	Small molecule	—	Oral
Subject	insulin glargine	Protein / enzyme biologic	—	Subcutaneous